Five Prime Thera Cmn (FPRX) 43.98 $FPRX Five Prime

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Five Prime Thera Cmn (FPRX) 43.98 $FPRX

Five Prime Announces Second Quarter 2016 Results and Provides Business Update
GlobeNewswire - Thu Aug 04, 3:06PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016.
FPRX: 43.98 (-2.27)

Research Report Initiation on These Biotech Stocks -- Tesaro, Cerus, Five Prime Therapeutics, and Intercept Pharma
PR Newswire - Thu Aug 04, 7:20AM CDT
The Biotech industry has been showing signs of strength in the previous days due to increased M&A activities and lesser regulatory and political pressures. On Tuesday, the iShares NASDAQ Biotechnology ETF rose to a high of $299 per share, as per CNBC. Stock-Callers.com takes a look at the following equities and see if they are poised for growth: Tesaro Inc. (NASDAQ: TSRO), Cerus Corp. (NASDAQ: CERS), Five Prime Therapeutics Inc. (NASDAQ: FPRX), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Learn more about these stocks by downloading their free report at:
CERS: 6.33 (-0.30), TSRO: 84.69 (-1.40), ICPT: 148.31 (-2.36), FPRX: 43.98 (-2.27)

Five Prime Therapeutics Presents Updated Data from Phase 1 trial of Single-Agent FPA144 at 2016 ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 8:25AM CDT
-- Initial data show a 33% confirmed objective response rate, 77% disease control rate, and 12-week progression free survival of 67% in 9 FGFR2b+ gastric cancer patients available for analysis
FPRX: 43.98 (-2.27)

Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting
GlobeNewswire - Sat Jun 04, 8:24AM CDT
-- Objective response rate of 39% and disease control rate of 100% in patients at or below the maximum tolerated dose level; progression free survival of 6.8 months, though data are still maturing
FPRX: 43.98 (-2.27)

Five Prime Therapeutics to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 8:30AM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Robert Sikorski, MD, PhD, Chief Medical Officer, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016, at 2:30 PM Eastern Daylight Time.
FPRX: 43.98 (-2.27)

Five Prime Therapeutics Appoints Dr. Robert Sikorski as Chief Medical Officer
GlobeNewswire - Wed Jun 01, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Robert Sikorski, M.D., Ph.D., to chief medical officer. In this role, he will oversee all clinical development (including clinical operations, pharmacovigilance, pharmacokinetics and biostatistics) and regulatory affairs, and will play a leading role in advancing Five Prime's immuno-oncology portfolio.
FPRX: 43.98 (-2.27)

How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 6.33 (-0.30), RDUS: 54.84 (-0.67), ARWR: 6.93 (-0.15), FPRX: 43.98 (-2.27)

Five Prime Therapeutics Announces Updated Clinical Data on FPA144 and FP-1039 to be Presented during 2016 ASCO Annual Meeting
GlobeNewswire - Wed May 18, 4:00PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that updated data from the ongoing clinical trials of FPA144 and FP-1039 will be presented during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 3-6, 2016, in Chicago. The presentation abstracts are now available online at the meeting website: https://iplanner.asco.org/am2016/#/. Information contained in the abstracts was as of the time of submission in February 2016. Five Prime intends to announce more detailed results at the time of the presentations at the ASCO Annual Meeting.
FPRX: 43.98 (-2.27)

Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis (PVNS)
GlobeNewswire - Thu May 12, 8:00AM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the advancement of FPA008 into the Phase 2 dose expansion portion of the ongoing Phase 1/2 trial in PVNS.
FPRX: 43.98 (-2.27)

Five Prime Therapeutics posts 1Q loss
Automated Insights - Thu May 05, 6:12PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Thursday reported a loss of $13 million in its first quarter.
FPRX: 43.98 (-2.27)

Five Prime Therapeutics to Announce First Quarter 2016 Financial Results and Host Conference Call on May 5
GlobeNewswire - Thu Apr 21, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2016 financial results on Thursday, May 5, 2016, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, May 5, 2016, at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.
FPRX: 43.98 (-2.27)

Top 4 Sales Growth Stocks
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 12:25PM CDT
Sales growth is an important indicator of a company's health and ability to sustain its business.
GILD: 78.38 (+0.46), TROW: 69.54 (-0.36), RMD: 66.69 (-0.53), FPRX: 43.98 (-2.27)

Five Prime Therapeutics Announces New Pre-Clinical Data on FPA144 Presented at the 2016 AACR Annual Meeting
GlobeNewswire - Mon Apr 18, 8:00AM CDT
-- Engineering of FPA144 for ADCC drives both innate and adaptive responses
FPRX: 43.98 (-2.27)

Looking for a Top Momentum Stock? 3 Reasons Why Five Prime Therapeutics (FPRX) is a Great Choice
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:28AM CDT
Five Prime Therapeutics is a great momentum stock and has been witnessing positive activity in the earnings estimate revision front as well
FPRX: 43.98 (-2.27)

Five Prime Therapeutics Announces FPA144 Will Be Featured During a Special Session at the 2016 AACR Annual Meeting
GlobeNewswire - Mon Apr 11, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that it will present the FPA144 program during a special session at the 2016 American Association for Cancer Research (AACR) Annual Meeting, being held April 16-20 in New Orleans.
FPRX: 43.98 (-2.27)

Can the Rally in Five Prime Therapeutics (FPRX) Shares Continue?
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:27AM CDT
Five Prime Therapeutics Inc (FPRX) has been on the move lately as the stock has risen by 38.2% in the past four weeks, and it is currently trading well above its 20-Day SMA
FPRX: 43.98 (-2.27)

Five Prime Therapeutics to Present at the 2016 Jefferies Immuno-Oncology Summit
GlobeNewswire - Fri Apr 01, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., Founder, Chief Executive Officer and Chairman of the Board, will present at the 2016 Jefferies Immuno-Oncology Summit on Friday, April 8, 2016, at 11:00 A.M. Eastern Daylight Time.
FPRX: 43.98 (-2.27)

Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 5%
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:25AM CDT
Five Prime Therapeutics, Inc. (FPRX) saw its shares rise just over 5% on the day.
AMAG: 23.83 (-0.06), FPRX: 43.98 (-2.27)

Five Prime Therapeutics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Thu Feb 04, 3:08PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Executive Vice President and Chief Business Officer, will present at the LEERINK Partners 5 Annual Global Healthcare Conference on Thursday, February 11, 2016 at 9:20 AM Eastern Standard Time.
FPRX: 43.98 (-2.27)

Five Prime Therapeutics Announces Key Executive Appointments
GlobeNewswire - Mon Feb 01, 3:05PM CST
-- Kevin Baker, Ph.D., appointed as Senior Vice President of Development Sciences
FPRX: 43.98 (-2.27)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 53

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 39

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 569

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 44

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 84

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 146

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 113

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Mastering Prescription Labels: Critical Insights for Safety

Updated Category News Views 0

Revolutionizing How We Approach Prescription Labels Prescription labels aren't just scraps of paper or stickers slapped on bottles; they're lifelines. The insight from pharmacy expert Sheldon Birch could turn a regular label into a powerful tool for health management. According to Birch, the label is often disregarded yet speaks volumes about the medication you've got in...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Line-Up of Athletes for Future Games in Abu Dhabi

Updated Category News Views 298

Global Stars Confirmed for Games of the Future 2025 Some of the biggest names in phygital sports and esports from around the world will head to Abu Dhabi for the ultimate showdown in next-gen sports from 18-23 December. Phygital International, the UAE-based promoter of phygital sports globally, has just confirmed the lineup for the Games of the Future Abu Dhabi 2025 (GOTF...

Continue Reading
Rhythm Pharmaceuticals Earnings Report: What to Watch For

Updated Category News Views 239

Eyes on Rhythm Pharmaceuticals: Earnings Just Around the Corner A steady hum of anticipation is in the air as Rhythm Pharmaceuticals (NASDAQ:RYTM) gears up to unveil its quarterly earnings on February 26, 2026. While investors hung onto the last report’s fallout, expectations this time are swirling around whether RYTM can turn things around after a slip last quarter....

Continue Reading
First Capital REIT Reports Impressive Q3 2024 Growth Metrics

Updated Category News Views 239

First Capital REIT's Strong Q3 Results Highlight Robust Performance First Capital Real Estate Investment Trust (TSX: FCR) has announced remarkable financial results for the third quarter ending September 30, indicating robust operational performance backed by strong leasing activities. The detailed report is made accessible to investors on the Trust's official website....

Continue Reading
Sherwin-Williams Faces Challenges After Lowering Earnings Outlook

Updated Category News Views 168

Sherwin-Williams Adjusts Earnings Projections Following Q2 Results The Sherwin-Williams Company (NYSE: SHW) recently faced some challenges after reporting lower-than-expected second-quarter earnings. With adjusted earnings per share (EPS) of $3.38, the results fell short of Wall Street's predictions, which had estimated $3.81 per share. The company's quarterly revenue,...

Continue Reading
Oculis Financial Results & Clinical Update for Q2 2024

Updated Category News Views 108

Oculis Reports Q2 Financial Results and Company Update Oculis Holding AG (NASDAQ: OCS; XICE: OCS), a global biopharmaceutical company focused on improving eye care, has shared its latest financial results and significant developments. The highlights from the second quarter ending June 30, 2024, illustrate the company's dedication to advancing its innovative clinical...

Continue Reading